Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Olaparib, and Fulvestrant in ER+/HER2- Breast Cancer with BRCA/HRR/MSI Alterations
NCT04053322Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Aug 2019
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib, fulvestrant in breast cancer, sponsored by Unicancer. Started Aug 2019; status: active, not recruiting.
02
Drugs
durvalumabolaparibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04053322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053322.